Market

Ascendis Pharma price target raised to $224 on strong Yorvipath demand

Ascendis Pharma price target raised to $224 on strong Yorvipath demand
Read More

Related Posts

US widens travel ban to more than 30 countries, Noem says

US widens travel ban to more than 30 countries, Noem says

Krna Matthew buys C1 Fund Inc (CFND) stock worth $10,005

Krna Matthew buys C1 Fund Inc (CFND) stock worth $10,005

SoFi prices $1.5 billion public offering of common stock

SoFi prices $1.5 billion public offering of common stock

US owner of major Russian agriculture firm says no plans to sell up

US owner of major Russian agriculture firm says no plan...

DocuSign stock price target lowered to $80 from $92 at Evercore ISI

DocuSign stock price target lowered to $80 from $92 at ...

Macy’s stock price target raised to $21 from $14 at Evercore ISI

Macy’s stock price target raised to $21 from $14 at Eve...